Patriot Scientific Corporation

Frequently Asked Questions

Q: What is the future direction of Patriot? Are additional M&A transactions planned? Is returning cash

to the shareholders an option?

A: Patriot is not currently

engaged in

an acquisition

proce

ss

. It has

divested of all non

essential

interests in activities that have required continued uses of cash. While we believe Patriot currently has a

relatively strong cash position, we

’ve

take

n

measures to preserve resources so that we are as prepared

as

possible to support our interests in the MMP Portfolio and meet all challenges, both known and

unforeseen. At this time

the

very important event

s

in determining Patriot’s future will be the outcome

in the current Northern California infringement litigati

on

and the actions before the International Trade

Commission

. Patriot

remains

supportive of a strategy to return cash to its shareholders however, no

action in this regard is expected to be undertaken until significant uncertainties surrounding the

busines

s, litigation, and the licensing program are resolved.

Q: Why aren’t all MMP

Portfolio licenses announced?

A: Not all MMP licenses are announced.

We believe that a

s a general rule the licensing program is

enhanced by the publicity associated with the

announcement of a new licensee. However, one reason

why a licen

se may not be announced is

the licensee

may require

confidentiality as

a condition to the

license agreement

. This may become

more

common

place

as

companies are increasingly approached by

parti

es representing intellectual property interests

. Companies don’t necessarily want to advertise that

they may

have been

targets for

patent infringement settlements.

Q: Why aren’t the licensee fees and terms for MMP licenses made public?

A:

The

rational

e for not disclosing licensing terms is to avoid this information setting minimum or upper

limits on future licensing deals, which would make it harder

in future negotiations with prospective

licensees.

P

otential licensees would have access to this inform

ation through Patriot’s public

filings

.

While we und

erstand

the desire of

our

shareholder

s to have this detailed information, it is in the best

interest of the licensing program not to disclose license details.

Q

: What is the current status of the USPTO re

examinations of the MMP Portfolio patents?

A: There have been

seventeen reexamination

challenges made on the MMP Portfolio

, all of which have

satisfactorily concluded

.

Q: Why don’t we ever hear about Holocom? Does Patriot still have an investment interest in Holocom?

A:

Patriot

continues to hold a preferred stock position in

Holocom

,

however its

results are not material

to our

business.

Q:

Why is there such a lack of t

ransparency

at Patriot?

A:

The perception that there is a lack of transparency stems largely from the nature of the licensing

business. It begins with the fact that most prospective licensees do not proactivel

y seek MMP Portfolio

licenses. This can create a potentially contentious environment where the rights of the Portfolio often

need to be aggre

ssively negotiated

with each licensor. Any information beyond what is not absolutely

essential or required by law

for public disclosure can be damaging to this effort. Similarly, litigation over

infringement, like most any litigation engaged in by corporations, is generally not commented on until

specific events are concluded.

Also

,

even in the best of times the li

censing business has

had

an episodic

element to it. Unless and until a reasonable basis for forecasting future results

becomes

apparent, it

would be inappropriate for us to make such speculations.

While we understand shareholder frustration

over transpar

ency, Patriot has

had

to work within the

se confines. Unfortunately, this can lead to

perceptions that there is an overall unreasonable or inappropriate lack of transparency

.

Finally,

there

are several important factors that

should be known which

contribut

e to the success of the licensing

business

and w

e have been careful to enumerate these in the Risk F

actors section of our annual report

on Form 10

K for the year ended May 31, 201

2

, and the quarterly report on Form 10

Q for the period

ended

February

2

8

, 20

1

3

. These are not

boilerplate

comments and we encourage you to read them

carefully.

Q: Does Patriot continue to purchase shares in the open market?

A: Patriot

periodically

purchase

s

shares

in the open market

within the

purview of the safe harbo

r of

Rule 10b

18 of the Securities Exchange Act of 1934.

Q: Are there significant stock option grants outstanding at the Board and management level for Patriot?

A: No. There are currently

575

,000 options granted which represent

s

less than

two

tenths of

one

percent of all outstanding shares.

Q: Is there significant insider trading in Patriot’s

stock?

A: There is not significant trading activity on the part of Patriot’s officers and Board. When trading

activity does occur, our

officers and

b

oard members are required to self report this activity with the

Securities and Exchange Commission on Form 4, Statement of Changes in Beneficial Ownership.

Officers

and directors

are subject to blackout periods restricting trading that at a

minimum typically covers

durations beginning with the conclusion of fiscal periods, through to the filing of quarter

ly

and annual

results on Forms 10

Q and 10

K. Accordingly,

officers and directors

are restricted from trading in the

Company’s stock for t

he majority of the year with

potentially

longer durations imposed in the event

there is material information that has yet to be released to the public.